This inventor holds 11 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 5 EPO patents. Top assignee: Novartis Ag. Active years: 2008-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008-2017
Title: The Innovative Contributions of Mark Meisenbach
Introduction
Mark Meisenbach is a notable inventor based in Durmenach, France. He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work focuses on developing novel compounds with potential therapeutic applications.
Latest Patents
Among his latest patents are the N-phenyl-2-pyrimidine-amine derivatives, which relate to novel amides and a process for preparing these amides. Another significant invention is the Somatostatin analogues, which provide a cyclo[{4-(NH—CH—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, showcasing interesting pharmaceutical properties.
Career Highlights
Mark has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Novartis Pharma GmbH. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in drug development.
Collaborations
Throughout his career, Mark has collaborated with esteemed colleagues such as Stephan Abel and Olivier Loiseleur. These partnerships have further enriched his work and expanded the impact of his inventions.
Conclusion
Mark Meisenbach's innovative contributions to the pharmaceutical field through his patents and collaborations highlight his significant role as an inventor. His work continues to influence the development of new therapeutic agents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile